- Home
- ANAB vs CSIQ Comparison
ANAB vs CSIQ Comparison
Compare ANAB & CSIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- CSIQ
- Stock Information
- Founded
- ANAB 2005
- CSIQ 2001
- Country
- ANAB United States
- CSIQ Canada
- Employees
- ANAB N/A
- CSIQ N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- CSIQ Semiconductors
- Sector
- ANAB Health Care
- CSIQ Technology
- Exchange
- ANAB Nasdaq
- CSIQ Nasdaq
- Market Cap
- ANAB 759.5M
- CSIQ 837.1M
- IPO Year
- ANAB 2017
- CSIQ 2006
- Fundamental
- Price
- ANAB $13.04
- CSIQ $11.38
- Analyst Decision
- ANAB Buy
- CSIQ Hold
- Analyst Count
- ANAB 11
- CSIQ 11
- Target Price
- ANAB $42.67
- CSIQ $19.31
- AVG Volume (30 Days)
- ANAB 775.9K
- CSIQ 1.9M
- Earning Date
- ANAB 11-05-2024
- CSIQ 12-05-2024
- Dividend Yield
- ANAB N/A
- CSIQ N/A
- EPS Growth
- ANAB N/A
- CSIQ N/A
- EPS
- ANAB N/A
- CSIQ N/A
- Revenue
- ANAB $57,172,000.00
- CSIQ $6,174,205,000.00
- Revenue This Year
- ANAB $233.68
- CSIQ N/A
- Revenue Next Year
- ANAB N/A
- CSIQ $22.66
- P/E Ratio
- ANAB N/A
- CSIQ $982.03
- Revenue Growth
- ANAB 282.17
- CSIQ N/A
- 52 Week Low
- ANAB $13.00
- CSIQ $10.60
- 52 Week High
- ANAB $41.31
- CSIQ $26.59
- Technical
- Relative Strength Index (RSI)
- ANAB 27.77
- CSIQ 43.94
- Support Level
- ANAB $15.11
- CSIQ $10.60
- Resistance Level
- ANAB $16.74
- CSIQ $12.05
- Average True Range (ATR)
- ANAB 1.48
- CSIQ 0.68
- MACD
- ANAB -0.31
- CSIQ -0.02
- Stochastic Oscillator
- ANAB 0.31
- CSIQ 25.91
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar power company. It is an integrated provider of solar power products, services, and system solutions. The company engages in designing, developing, and manufacturing solar ingots, wafers, cells, modules, and other solar power products. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. Its Recurrent segment primarily comprises solar and battery storage project development and sale, O&M and asset management services for operational projects, sale of electricity, and investment in retained assets.